Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Chronic Obstructive Pulmonary Patients is a defined by persistent airflow limitation that is usually progressive and associated with an enhanced chronic inflammatory response in the airways and the lung to noxious particles or gases. It is associated with an atrophy of the skeletal muscle that impairs the patient's prognosis. The biological mechanisms of this muscle atrophy have not been elucidated, and the "spill-over theory" has recently emerged. Indeed, in COPD patients, the pulmonary inflammation is associated with a systemic low-grade inflammation, and the increased pro-inflamatory molelcules in the blood - which constitute the cellular micro-environement of the muscle fibre - could activate the mechanisms of the cell atrophy.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Healthy subjects | Determination of pro-inflammatory plasma factors at Healthy subjects aged from 35 to 85 years old |
| |
| COPD patients | Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Determination of pro-inflammatory plasma factors | Other | Determination of pro-inflammatory plasma factors at COPD patients aged from 35 to 85 years old and Healthy subjects aged from 35 to 85 years old |
| Measure | Description | Time Frame |
|---|---|---|
| Myotube diameter of in vitro cultured myotubes | Myotube diameter of in vitro cultured myotubes from healthy subjects, exposed to the serum of healthy controls and COPD patients | 6 days |
| Measure | Description | Time Frame |
|---|---|---|
| Expression and translation of markers of | Expression and translation of markers of anabolic and catabolic pathways | 6 days |
| Measure | Description | Time Frame |
|---|---|---|
| Level of pro-Inflamatory markers | Level of pro-Inflamatory markers in the serum | 6 days |
Inclusion Criteria:
35 to 85 years old
Exclusion Criteria:
Not provided
Not provided
Chronic Obstructive Pulmonary Patients
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Maurice HAYOT, MD, PhD | University Hospital, Montpellier | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Uhmontpellier | Montpellier | 34290 | France |
NC
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D029424 | Pulmonary Disease, Chronic Obstructive |
| D001284 | Atrophy |
| ID | Term |
|---|---|
| D008173 | Lung Diseases, Obstructive |
| D008171 | Lung Diseases |
| D012140 | Respiratory Tract Diseases |
| D002908 | Chronic Disease |
Not provided
Not provided
Not provided
Not provided
Not provided
| D020969 |
| Disease Attributes |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D020763 | Pathological Conditions, Anatomical |